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Background: In complex with its cofactor UAF1, the USP1 deubiquitinase plays an important role in cellular
processes related to cancer, including the response to DNA damage. The USP1/UAF1 complex is emerging as a
novel target in cancer therapy, but several aspects of its function and regulation remain to be further clarified.
These include the role of the serine 313 phosphorylation site, the relative contribution of different USP1 sequence
motifs to UAF1 binding, and the potential effect of cancer-associated mutations on USP1 regulation by autocleavage.
Methods: We have generated a large set of USP1 structural variants, including a catalytically inactive form (C90S),
non-phosphorylatable (S313A) and phosphomimetic (S313D) mutants, deletion mutants lacking potential UAF1
binding sites, a mutant (GG/AA) unable to undergo autocleavage at the well-characterized G670/G671 diglycine
motif, and four USP1 mutants identified in tumor samples that cluster around this cleavage site (G667A, L669P, K673T
and A676T). Using cell-based assays, we have determined the ability of these mutants to bind UAF1, to reverse DNA
damage-induced monoubiquitination of PCNA, and to undergo autocleavage.
Results: A non-phosphorylatable S313A mutant of USP1 retained the ability to bind UAF1 and to reverse PCNA
ubiquitination in cell-based assays. Regardless of the presence of a phosphomimetic S313D mutation, deletion
of USP1 fragment 420–520 disrupted UAF1 binding, as determined using a nuclear relocation assay. The UAF1
binding site in a second UAF1-interacting DUB, USP46, was mapped to a region homologous to USP1(420–520).
Regarding USP1 autocleavage, co-expression of the C90S and GG/AA mutants did not result in cleavage, while the
cancer-associated mutation L669P was found to reduce cleavage efficiency.
Conclusions: USP1 phosphorylation at S313 is not critical for PCNA deubiquitination, neither for binding to UAF1 in a
cellular environment. In this context, USP1 amino acid motif 420–520 is necessary and sufficient for UAF1 binding. This
motif, and a homologous amino acid segment that mediates USP46 binding to UAF1, map to the Fingers sub-domain
of these DUBs. On the other hand, our results support the view that USP1 autocleavage may occur in cis, and can
be altered by a cancer-associated mutation.Background
Ubiquitin Specific Protease 1 (USP1) is a human deubi-
quitinase (DUB) that plays an important role in the
regulation of the cellular response to DNA damage and
is also involved in the control of cell differentiation
(reviewed in [1]). USP1 is a 785 amino acid protein,* Correspondence: josean.rodriguez@ehu.es
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article, unless otherwise stated.whose three-dimensional structure has not yet been
solved. Structural analysis of other USP family members,
such as USP7, has shown that the catalytic domain of
these enzymes adopts a fold that resembles an open
right hand with three sub-domains termed Fingers, Palm
and Thumb [2,3]. A detailed sequence alignment analysis
has further revealed that the USP core catalytic domain
can be divided into six conserved boxes (boxes 1–6), and
that several of these enzymes, including USP1, contain
additional non-conserved domains inserted between thed Central. This is an Open Access article distributed under the terms of the
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mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Olazabal-Herrero et al. Molecular Cancer  (2015) 14:33 Page 2 of 14boxes that may play a regulatory role [4]. USP1 bears one
of the largest catalytic domains within the USP family,
which includes two inserted domains between boxes 2
and 3, and between boxes 5 and 6 [4].
One of the best-characterized functions of USP1 in the
DNA damage response is as a regulator of Proliferating
Cell Nuclear Antigen (PCNA) ubiquitination [5]. Following
DNA damage that stalls progression of the replication fork,
PCNA is monoubiquitinated to promote the recruitment
of translesion synthesis (TLS) DNA polymerases, which
can bypass the lesion [6]. USP1 deubiquitinates PCNA,
thus contributing to prevent unscheduled recruitment of
error-prone TLS DNA polymerases [5].
USP1 carries out its function in the context of a hetero-
dimeric complex with its cofactor USP1-Associated Factor
1 (UAF1). UAF1 has been shown to stabilize USP1 [7] and
to allosterically increase its catalytic activity, which is
very low in the absence of the cofactor [7,8]. UAF1 also
contributes to target USP1 to its nuclear substrates [9].
In addition to USP1, UAF1 also binds to and regulates
the activity of two other members of the USP family,
USP12 and USP46 [10].
Overexpression of USP1 has been reported in osteosar-
coma [11] and non-small cell lung cancer (NSCLC) [1,12],
among other cancer types. In addition, USP1 mutations
have been identified, albeit at a low frequency, in tumor
samples [13]. The functional effect of these cancer-
associated USP1 mutations remains to be investigated.
Importantly, several inhibitors of the USP1/UAF1 com-
plex have been recently shown to act synergistically with
cisplatin in cancer-derived cell lines [1,14,15], suggesting
that this complex may represent a valid therapeutic target
in cancer. The development and implementation of USP1-
targeted therapies will benefit from a more detailed know-
ledge of how the function of this DUB is regulated, and
how this regulation can be affected by cancer-related
mutations.
Several regulatory mechanisms converge to determine
the levels, localization and activity of USP1 (reviewed in
[1]). These mechanisms include phosphorylation and
autocleavage.
Phosphorylation at serine 313 (S313), within the first
inserted domain, was initially reported to regulate cell cycle-
dependent degradation of USP1. Thus, cyclin-dependent
kinase 1 (CDK1)-mediated phosphorylation of S313 during
M phase was shown to prolong the stability of USP1 pre-
sumably by preventing its degradation by the anaphase-
promoting complex/cyclosome [16]. More recently, S313
phosphorylation has been reported to be critical for UAF1
interaction and USP1 catalytic activity in vitro [17]. In this
study, using pull-down assays with purified recombin-
ant proteins, the UAF1-binding motif was mapped to
USP1 amino acid region 235–408 [17]. In contrast, using
cell-based assays, we have mapped the UAF1-bindingregion in USP1 to a 100 amino acid motif comprising
residues 420–520, which does not include the S313
phosphorylation site [18]. It is, therefore, necessary to
clarify these conflicting results, and to determine to what
extent these two amino acid motifs, and the S313 phos-
phorylation site, contribute to USP1/UAF1 interaction.
Another important regulatory mechanism involves the
autocleavage of USP1 at a diglycine motif (G670/G671)
located within its second inserted domain [5]. The cleavage
event generates a longer N-terminal fragment (residues
1–671) and a shorter C-terminal fragment (residues
672–785), which are subsequently degraded by the pro-
teasome [5,19]. It remains to be elucidated if USP1
autocleavage occurs in cis (intramolecularly) or in trans
(intermolecularly) and, more importantly, if USP1 auto-
cleavage could be altered by cancer-associated USP1
mutations that cluster around the G670/G671 motif.
In the present work, we use site-directed mutagenesis
and cell-based functional assays to carry out a detailed
structure-function analysis of human USP1. Our results
indicate that the S313 phosphorylation site is not critical
for USP1 binding to UAF1 or for PCNA deubiquitination
in a cellular environment. Furthermore, we show that two
homologous amino acid segments in USP1 (420–520) and
USP46 (165–259), which are predicted to correspond to
the Fingers sub-domains, mediate binding of these DUBs
to UAF1. Moreover, we provide some experimental evi-
dence suggesting that USP1 autocleavage may occur in cis.
Finally, we identify a cancer-associated mutation in a resi-
due adjacent to the cleavage site (L669P), that hampers
USP1 autocleavage.
Results
UAF1 binds and stabilizes a non-phosphorylatable S313A
mutant version of USP1 in cell-based assays
It has been recently reported that phosphorylation of
USP1 at S313 is necessary for the interaction of this
DUB with its cofactor UAF1 [17]. Since only in vitro evi-
dence for S313 phosphorylation-regulated USP1/UAF1
interaction has been provided, we decided to evaluate
the role that this phosphorylation site may have in regu-
lating USP1 binding to UAF1 in a cellular context. To
this end, we generated non-phosphorylatable (S313A) and
phosphomimetic (S313D) mutant versions of USP1, and
tested their ability to interact with UAF1 in cell-based
assays. We have previously described a cellular relocation
assay to evaluate USP1/UAF1 interaction [18]. This assay
is based on the nuclear accumulation of UAF1 induced by
USP1 co-expression and, by using fluorescently-tagged
versions of these proteins, the results can be observed
in live cells, before processing for microscopy analysis.
As shown in Figure 1A, UAF1-mRFP was predominantly
located in the cytoplasm of both live and fixed 293T
cells when co-expressed with YFP (negative control).
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(Additional file 1A). Consistent with our previous report
[18], UAF1-mRFP accumulated in the nucleus when
co-expressed with GFP-USP1. Importantly, both GFP-
USP1S313A and GFP-USP1S313D were able to relocate
UAF1-mRFP to the nucleus, suggesting that both mu-
tants are still able to interact with UAF1. Similar results
were obtained when endogenous USP1 gene expressionFigure 1 UAF1 binds and stabilizes a non-phosphorylatable S313A m
show representative examples of 293T cells co-expressing UAF1-mRFP with Y
Left panels show live cell images, whereas right panels show images of fixed
(DNA panels). UAF1-mRFP is cytoplasmic when co-expressed with YFP, but re
GFP-USP1S313A and GFP-USP1S313D. B. Co-IP analysis of co-transfected 293
GFP-USP1 wild type, GFP-USP1S313A and GFP-USP1S313D. A section of the
WCE, whole cell extract. C. Immunoblot analysis of 293T cells transfected
(−) or in combination with Xpress-UAF1 (+). Anti-GFP antibody was used
detect Xpress-UAF1. β-actin was used as a loading control. UAF1 co-expr
USP1S313A and GFP-USP1S313D to a similar extent. The lower molecular we
N-terminal fragment that results from USP1 autocleavage at the G670/G6was down-regulated using siRNA (Additional file 1B,C).
In line with the results of the relocation assay, co-
immunoprecipitation (co-IP) analysis (Figure 1B) re-
vealed that both GFP-USP1S313A and GFP-USP1S313D
co-immunoprecipitated Xpress-UAF1 as efficiently as
wild type GFP-USP1.
Next, we compared the effect of UAF1 expression on
the stability of the different USP1 variants, since UAF1utant version of USP1 in cell-based assays. A. Confocal images
FP (vector), GFP-USP1 wild type (WT), GFP-USP1S313A or GFP-USP1S313D.
cells. Fixed cells were counterstained with Hoechst to show the nuclei
locates to the nucleus when co-expressed with GFP-USP1 wild type,
T cells, showing that Xpress-UAF1 readily co-immunoprecipitates with
membrane stained with Ponceau is shown to gauge protein loading.
with GFP-USP1 wild type, GFP-USP1S313A and GFP-USP1S313D, alone
to detect GFP-USP1 proteins and anti-Xpress antibody was used to
ession markedly increases the levels of GFP-USP1 wild type, GFP-
ight band in (+) samples corresponds to the well-characterized
71 diglycine motif (see below).
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deed, a dramatic increase in the level GFP-USP1 was
observed in 293T cells co-transfected with Xpress-UAF1
(Figure 1C). Of note, the increase in USP1 levels was ac-
companied by the appearance of a lower molecular weight
band. As further discussed below, this band most likely
corresponds to the amino-terminal fragment of USP1
resulting from its cleavage at the well-characterized
G670/G671 autocleavage site [5]. No differences in UAF1-
induced stabilization or cleavage were observed between
the wild type USP1 and the S313A or S313D mutants.
The finding that the non-phosphorylatable S313A
mutant version of USP1 binds and is stabilized by UAF1
in our cell-based assays indicates that phosphorylation at
S313 is not critical for USP1/UAF1 complex formation in
a cellular context.
The non-phosphorylatable USP1S313A mutant maintains
its PCNA deubiquitinating activity
The S313A mutation has been reported to drastically re-
duce the catalytic activity of USP1 in in vitro assays
using an artificial fluorogenic substrate [17]. We decided
to test the effect of this mutation on the ability of USP1
to deubiquitinate a physiologically relevant substrate of
this enzyme, monoubiquitinated PCNA (ubPCNA).
As previously shown [5], we found that treatment of
293T cells with hydroxyurea (HU) induced PCNA
monoubiquitination (Additional file 2), which was re-
duced by ectopic expression of wild type GFP-USP1,Figure 2 USP1-mediated PCNA deubiquitination is not abrogated by th
with Xpress-UAF1 and YFP-vector, GFP-USP1 wild type (WT) or the catalytically
treated (+) with 4 mM hydroxyurea (HU) for 24 h. Using an anti-PCNA antibod
slightly above the non-ubiquitinated form (PCNA). A short-exposure time ima
showing only ubPCNA with longer exposure time are shown. The dotted
exposure of the same gel. Expression of wild type GFP-USP1 decreased HU-in
did not. Expression of β-actin was used as a control for equal loading of the p
lysis of 293T cells co-transfected with Xpress-UAF1 and GFP-USP1 wild type, G
HU for 24 h. The ratio of ubiquitinated to non-ubiquitinated PCNA (ubPCNA/P
bands. The graph on the right shows the results of this analysis. The ubP
GFP-USP1S313A and GFP-USP1S313D, but higher in cells expressing the cata
SEM of 7 independent experiments.but not by expression of a catalytically inactive C90S
mutant (Figure 2A). Next, 293T cells were co-transfected
with plasmids encoding Xpress-UAF1 and GFP-USP1 wild
type, GFP-USP1C90S, GFP-USP1S313A or GFP-USP1S313D,
and treated with HU. As shown in Figure 2B, both S313A
and S313D mutants, but not the C90S mutant, were
able to decrease HU-induced PCNA monoubiquitination.
Nevertheless, the ratio of ubiquitinated to non-ubiquitinated
PCNA (ubPCNA/PCNA ratio) was repeatedly observed in
several independent experiments to be slightly higher in
cells expressing GFP-USP1S313A and slightly lower in cells
expressing GFP-USP1S313D in comparison to cells expressing
wild type GFP-USP1. From these results, we conclude that
phosphorylation at S313 is not necessary for USP1-mediated
PCNA deubiquitination in HU-treated cells, although it
might contribute to modulate this activity.
Side-by-side comparison of two reported UAF1-binding
sites in USP1 using the nuclear relocation assay
The identity of the UAF1 binding region(s) in USP1 is a
matter of some controversy (Figure 3A). Using the re-
location assay and co-IP, the UAF1-binding site has been
mapped to a motif comprising USP1 residues 420–520
[18]. On the other hand, using in vitro binding assays
with purified recombinant proteins, UAF1 has been re-
ported to bind USP1 amino acid segment 235–408, which
corresponds to the non-conserved domain inserted be-
tween boxes 2 and 3 of USP1 [17]. The 235–408 segment
includes USP1 nuclear localization signals (NLSs) and thee S313A mutation. A. Immunoblot analysis of 293T cells co-transfected
inactive GFP-USP1C90S. Cells were either left untreated (−), or were
y, monoubiquitinated PCNA (ubPCNA) is detected as a band migrating
ge showing both PCNA and ubPCNA, as well as a cropped image
line indicates that a panel is a composite of two images from a single
duced PCNA monoubiquitination, whereas expression of GFP-USP1C90S
rotein samples. B. On the left, representative example of immunoblot ana-
FP-USP1C90S, GFP-USP1S313A or GFP-USP1S313D, and treated with 4 mM
CNA ratio) was determined by densitometry analysis of the immunoblot
CNA/PCNA ratio was similar in cells expressing wild type GFP-USP1,
lytically inactive GFP-USP1C90S. The data represent the mean and
Figure 3 Side-by-side comparison of two reported UAF1-binding sites in USP1 using a nuclear relocation assay. A. Schematic representation
of USP1 and the deletion mutants used in the analysis. The two reported UAF1 binding sites are highlighted: in orange, the 235–408 segment reported
by Villamil et al. [17]; in green, the 420–520 segment reported by García-Santisteban et al. [18]. The location of USP1 nuclear localization signals (NLSs, in
red), and the S313 phosphorylation site is also shown. S313 wild type and S313D phosphomimetic mutants of USP1(235–408) and USP1(del420-520)
were used. B. Confocal images showing representative examples of the results using the in vivo nuclear relocation assay. 293T cells were co-transfected
with UAF1-mRFP and GFP-USP1 full length (FL), GFP-USP1(420–520), YFP-USP1(235–408), YFP-USP1(235–408)S313D, YFP-USP1(del420-520) and YFP-USP1
(del420-520)S313D. Cells were counterstained with Hoechst to show the nuclei (DNA panels). UAF1-mRFP clearly relocates to the nucleus when
co-expressed with GFP-USP1 full length and GFP-USP1(420–520), but not with the remaining deletion mutants. C. Graph showing the results
of a semiquantitative analysis of the nuclear relocation assay samples. Slides were coded and the nuclear (N), nuclear/cytoplasmic (N/C) or
cytoplasmic (C) localization of UAF1-mRFP was determined in at least 100 cells per slide. The results (mean and SEM) of three independent
experiments are shown in the graph.
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mimetic S313D mutant version of this segment was found
to interact with UAF1 in vitro [17]. In an attempt to gauge
the contribution of these two USP1 regions to UAF1-
binding in a cellular context, we carried out a side-by-side
test to compare USP1(420–520) and USP1(235–408) in
the UAF1-relocation assay. S313 wild type and S313D
phosphomimetic versions of USP1(235–408) were tested.
In addition, S313 wild type and S313D versions of a frag-
ment USP1(del420-520), lacking the 420–520 motif, were
also included in the test.
YFP- or GFP-tagged versions of these USP1 variants
were co-expressed with UAF1-mRFP in 293T cells. Full-
length GFP-USP1 was used as a positive control. As
described before [18], one of USP1 NLSs was used to
ensure nuclear accumulation of the 420–520 motif.Figure 3B shows representative examples of the results
obtained in the nuclear relocation assay. The percent-
age of cells showing nuclear (N), nuclear/cytoplasmic
(N/C) or cytoplasmic (C) localization of UAF1-mRFP
was determined in cells co-expressing the different
GFP-USP1 variants, and the results of three independ-
ent assays are represented in Figure 3C. In line with
our previous findings [18], full-length USP1 and the
USP1(420–520) fragment induced a complete reloca-
tion of UAF1-mRFP to the nucleus. In contrast, UAF1-
mRFP remained largely cytoplasmic when co-expressed
with the other USP1 variants tested, including USP1
(235–408)S313D and USP1(del420-520)S313D. These re-
sults indicate that USP1 amino acid motif 420–520 is
both necessary and sufficient for UAF1 binding in a cel-
lular environment.
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mRFP nuclear relocation contrasts with the reported
ability of this fragment to interact with UAF1 in vitro
[17]. These contrasting findings might result from com-
petition between UAF1 and other proteins for binding to
this USP1 fragment, an event that may occur in cellular
assays but not in in vitro assays with purified proteins.
Since the 235–408 motif overlaps with USP1 NLSs, we
hypothesized that competition with the nuclear import
machinery might prevent UAF1 binding to this motif in
the cellular environment (Additional file 3A). To test
this possibility, a variant of the USP1(235–408) frag-
ment, termed USP1(235-408NLSm+NLS), was generated
(Additional file 3A). This variant bears inactivating muta-
tions in USP1 NLSs [18], and its nuclear localization is
mediated by a heterologous NLS from the SV40 large T
antigen (SV40NLS) fused to its amino terminus. USP1
(235-408NLSm+NLS) and the phosphomimetic USP1
(235-408NLSm+NLS)S313D remained unable to induce
UAF1-mRFP relocation to the nucleus (Additional file 3B).
The possibility that the NLS-inactivating mutations might
simultaneously interfere with UAF1 binding cannot be
formally ruled out, but these results suggest that the in-
ability of USP1(235–408) to promote UAF1 relocation
cannot be ascribed to competition with the nuclear im-
port machinery.
Homologous amino acid motifs, mapping to the Fingers
sub-domain, mediate binding of USP1 and USP46 to UAF1
In addition to USP1, two other DUBs, USP12 and USP46
interact with UAF1 [10], but the UAF1-binding sites in
these DUBs have not yet been mapped. Considering the
importance of UAF1 interaction for the enzymatic activity
of these proteins [10,20], we reasoned that the critical
UAF1-binding sequences would be conserved among
these different DUBs. In order to test this possibility,
and to gain further insight into UAF1/DUB interaction,
we used CLUSTALW to align USP1, USP46 and USP12
amino acid sequences (Figure 4A) and BLAST to assess
the similarity of USP1 fragments 235–408 and 420–520
with USP12 and USP46 (not shown). Not surprisingly,
given that the 235–408 fragment maps to a non-conserved
inserted domain [4], the degree of similarity of this frag-
ment with USP12 (BLAST score 14.2) and USP46 (BLAST
score 16.5) was markedly lower than that of the 420–520
fragment (BLAST score 52.0 with USP12 and 53.1 with
USP46).
USP1 420–520 segment was found to be homologous
to a central amino acid segment in USP12 and USP46.
Therefore, we decided to carry out a deletion analysis
followed by cell-based interaction assays to determine if
this central motif mediates the binding of these other
DUBs to UAF1. Since USP12 and USP46 are highly
homologous proteins, we limited our analysis to USP46.As shown in Figure 4B, three deletion mutants of USP46
tagged with GFP were generated: an amino-terminal frag-
ment (1–164), a central fragment (165–259), encompassing
the region of homology to USP1(420–520), and a carboxy-
terminal fragment (243–266). In agreement with a
previous report [21], we found that USP46-GFP is a
cytoplasmic protein (Additional file 4). Thus, the SV40
NLS was fused to its amino terminus in order to force its
nuclear import to carry out the UAF1-mRFP relocation
assay (Additional file 4). This assay, (Figure 4C) as well as
a subsequent co-IP analysis (Figure 4D), revealed that the
UAF1-binding motif of USP46 lies within the 165–259
fragment. Thus, homologous amino acid sequences in
USP1 and USP46 mediate binding to UAF1. Since the
three-dimensional structure of USP1 and USP46 has
not yet been reported, we used the SWISS-MODEL
web tool [22] to model the structure of the catalytic do-
mains of these DUBs using the structure of USP7 cata-
lytic domain as a template. This model revealed that
the UAF1 binding motifs of USP1 and USP46 map to
their Fingers sub-domains (Figure 4E).
Does autocleavage of USP1 at the G670/G671 motif occur
in cis or in trans?
USP1 cleaves itself after the G670/G671 diglycine motif
located near its carboxy-terminal end, within its second
inserted domain. This autocleavage event produces two
fragments that are subsequently degraded, and it was
originally described as a mechanism that inactivates USP1
to allow for robust PCNA ubiquitination after UV-induced
DNA damage [5]. Studies in chicken cells have shown that
UV may also induce USP1 cleavage at other sites, which is
not dependent on USP1 catalytic activity [23].
Previous reports have also shown that USP1 autoclea-
vage at the G670/G671 motif can also occur in the ab-
sence of UV treatment [5,7]. In line with these findings,
we noted (see Figures 1C and 2B) that GFP-USP1 wild type,
but not the catalytically inactive mutant GFP-USP1C90S,
readily undergoes cleavage when co-expressed with Xpress-
UAF1 in 293T cells. This observation provides a con-
venient experimental system to further investigate USP1
autocleavage.
One of the aspects of USP1 autocleavage that remains
to be elucidated is whether it occurs intramolecularly
(in cis) or intermolecularly (in trans) (Figure 5A). The
three-dimensional structure of USP1 has not yet been
solved, and the autocleavage motif lies within a non-
conserved domain whose structure cannot be reliably
modelled using other USPs as template. Thus, it re-
mains unknown if the cleavage site of a USP1 molecule
can reach the catalytic site of the same molecule for the
cleavage to occur in cis. In an attempt to shed some light
on this issue, we devised the experiment illustrated in
Figure 5B. A catalytically inactive mutant (USP1C90S),
Figure 4 (See legend on next page.)
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Figure 4 Homologous amino acid motifs, mapping to the Fingers sub-domain, mediate binding of USP1 and USP46 to UAF1. A. Alignment
of USP1, USP46 and USP12 aminoacid sequences using CLUSTALW. USP1 aminoacid segment 420–520 and the homologous regions of USP46 and
USP12 are highlighted in blue. B. Schematic representation of different GFP-tagged USP46 deletion mutants used to map its UAF1-binding motif. A
heterologous nuclear localization signal (SV40 NLS) was fused to the amino terminal end of each fragment to ensure its nuclear accumulation C. Results
of the UAF1 nuclear relocation assay with USP46 fragments. Confocal microscopy images show representative examples of 293T cells co-expressing
UAF1-mRFP (red) and the different USP46 protein fragments (green). Cells were counterstained with Hoechst to show the nuclei (DNA panels). Nuclear
relocation of UAF1-mRFP is induced by full length (FL) and the 165–259 fragment, but not by the 1–164 or the 243–366 fragments. D. Co-IP analysis of
co-trasfected 293T cells, showing that Xpress-UAF1 co-immunoprecipitates with full-length USP46 and with the fragment encompassing residues
165–259, but not with the other two fragments tested. The dotted line indicates that the panel is a composite of two images from a single
exposure of the same gel. WCE, whole cell extract. A section of the membrane stained with Ponceau is shown to gauge protein loading. E. Modeled
structure of USP1 (left) and USP46 (right) catalytic domains using SWISS-MODEL and the USP7 structure 1NB8 [2] as a template. The Thumb, Palm and
Fingers sub-domains are indicated. The UAF1-binding sites are highlighted in red (USP1 residues 420–520) or blue (USP46 residues 165–259).
Olazabal-Herrero et al. Molecular Cancer  (2015) 14:33 Page 8 of 14as well as a mutant with alanine substitutions at the
G670/G671 cleavage site (USP1GG/AA) cannot undergo
autocleavage in cis. However, it has been shown that
USP1GG/AA maintains its enzymatic activity [5,23] and, in
fact, it efficiently deubiquitinates ubPCNA when trans-
fected in 293T cells (Additional file 5A). Therefore, we
reasoned that, if USP1 autocleavage occurs in trans,
USP1GG/AA molecules could cleave USP1C90S molecules.
To test this hypothesis, GFP-USP1GG/AA and GFP-
USP1C90S were either individually or simultaneously
co-expressed with Xpress-UAF1 in 293T cells. Wild type
GFP-USP1 was used as a positive control. As shown in
Figure 5C, simultaneous co-expression of GFP-USP1GG/AA
and GFP-USP1C90S did not result in cleavage. It re-
mains certainly possible that, in this experimental set-
ting, GFP-USP1GG/AA and GFP-USP1C90S molecules did
not come into close enough proximity for cleavage to
occur in trans and, therefore, our results do not com-
pletely exclude the possibility of USP1 trans cleavage.
However, our findings support the view that USP1 auto-
cleavage occurs in cis.
A cancer-associated missense mutation in USP1 hampers
autocleavage
A second aspect about USP1 autocleavage that has not
yet been investigated is the possibility that it could be al-
tered by naturally occurring cancer-associated mutations.
Although USP1 gene mutations are not a frequent event
in human tumors, the Catalogue Of Somatic Mutations in
Cancer (COSMIC) [24] database includes over thirty mis-
sense mutations in USP1, whose functional effect has not
yet been tested. Four of these mutations (G667A, L669P,
K673T and A676T) cluster within a ten amino acid
segment encompassing the G670/G671 autocleavage
site (Figure 5D). To determine if any of these cancer-
associated mutations might alter USP1 cleavage, we
used site-directed mutagenesis to introduce each of these
amino acid changes into GFP-USP1, and we co-expressed
these proteins with Xpress-UAF1 in 293T cells. It is im-
portant to note that none of these mutations disrupted
USP1/UAF1 interaction, according to the results of anuclear relocation assay (Additional file 5B). Immunoblot
analysis (Figure 5E, and Additional file 5C) revealed that
GFP-USP1G667A, GFP-USP1K673T and GFP-USP1A676T
were cleaved to a similar extent as wild type GFP-USP1,
while cleavage of the GFP-USP1L669P mutant was much
less efficient.
We next tested the ability of these cancer-associated
USP1 mutants to deubiquitinate PCNA. As shown in
Figure 5F, the four tested cancer-associated mutants readily
decreased HU-induced PCNA ubiquitination in 293T cells.
In contrast, cells transfected with the YFP vector or the
catalytically inactive GFP1C90S (negative controls) showed
higher levels of ubPCNA.
Finally, we aimed to evaluate the possibility that the
cancer-related mutants might alter the cis/trans mode of
cleavage. To this end, we introduced the catalytic-site
mutation C90S into each cancer-related mutant construct.
As shown in Additional file 5C, the C90S mutation ren-
dered these mutants unable to undergo autocleavage.
These double mutants also failed to undergo cleavage
when expressed in combination with GFP-USP1GG/AA
(Figure 5G), suggesting that the cancer-related mutations
tested here do not alter the cis/trans mode of cleavage of
USP1.
Discussion
Since the discovery, nearly a decade ago, that USP1 plays
an important role in the cellular response to DNA dam-
age [5,25], significant advances have been made on the
understanding of the function and regulation of this
DUB. It has been shown, for example, that USP1 carries
out its cellular activities in the context of a heterodimeric
complex with UAF1, which enhances the stability and the
enzymatic activity of the DUB [7,8]. The stability and
activity of USP1 have been shown to be further regu-
lated by several mechanisms, including CDK-mediated
phosphorylation at the S313 residue [16] and cleavage
by either itself [5] or other proteases [23,26].
The USP1/UAF1 complex is emerging as a novel tar-
get for cancer treatment (reviewed in [1]), and inhibitors
of USP1 catalytic activity have been reported to reverse
Figure 5 (See legend on next page.)
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Figure 5 USP1 autocleavage: assessing cis/trans mode of cleavage and the effect of cancer-associated mutations. A. Representation of
USP1 showing the catalytic triad (C90/H593/D751, green spheres) and the autocleavage site (G670/G671, blue spheres). Below, potential cis/trans
autocleavage modes. B. Experiment used to assess cleavage mode. The C90S and GG/AA mutants (mutated residues in red) are unable to undergo cis
autocleavage. If autocleavage occurs in trans, co-expression of both mutants could lead to cleavage of GFP-USP1C90S by GFP-USP1GG/AA.
C. Immunoblot analysis of cells expressing Xpress-UAF1 and GFP-USP1 constructs. Autocleavage was detected in cells transfected with wild
type GFP-USP1, but not with GFP-USP1C90S or GFP-USP1GG/AA. No cleavage was observed upon co-expression of GFP-USP1C90S and GFP-USP1GG/AA,
suggesting that trans cleavage does not occur. D. Location of cancer mutations [24] near USP1 autocleavage site. E. Immunoblot analysis of cells
expressing Xpress-UAF1 and different USP1 mutants. GFP-USP1G667A, GFP-USP1K673T and GFP-USP1A676T are cleaved as efficiently as wild type
USP1, whereas GFP-USP1L669P is less efficiently cleaved. F. PCNA ubiquitination in 293T cells treated with 4 mM HU for 24 h. An example of
immunoblot results is shown (left). The dotted line indicates that the panel is a composite of two images from a single exposure of the same
gel. UbPCNA/PCNA ratio was determined by densitometry and the results (mean and SEM of 3 independent experiments) are shown in the
graph (right). Cancer-associated mutations did not alter the ubPCNA/PCNA ratio. G. The C90S mutation (S90) was introduced into each
cancer-related mutant construct, rendering these mutants unable to undergo cis autocleavage (Additional Figure 5C). These double mutants
were expressed together with GFP-USP1GG/AA to evaluate if they undergo trans cleavage. No autocleavage band was observed with any of the
cancer-related/(S90) mutants upon co-expression with GFP-USP1GG/AA, suggesting that the cancer-related mutations tested do not alter the
cis/trans mode of cleavage.
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in NSCLC cells [14,15] and to inhibit the growth of
leukemic cell lines [27]. Further development of the thera-
peutic potential of this deubiquitinase complex would
benefit from a better understanding of several aspects
of its regulation that remain controversial, incompletely
characterized or unexplored.
For example, protein-protein interactions are increas-
ingly regarded as promising therapeutic targets in cancer
[28] and thus, characterizing the molecular determinants
of USP1/UAF1 interaction may be important to guide ef-
forts aimed to disrupt this interaction with therapeutic
purposes. In this regard, phosphorylation at the S313 resi-
due has been recently reported to be critical for USP1
activity and interaction with UAF1 in an in vitro setting
[17]. Here, we show that a non-phosphorylatable mu-
tant USP1S313A is still able to bind UAF1 when tested in
cell-based assays. These assays were carried out using ec-
topically expressed proteins, but are, in our view, closer to
a physiological setting than in vitro binding assays with
purified proteins. In particular, the nuclear relocation assay
with fluorescently-tagged proteins allows for visualization
of the results in live cells. Of note, USP1/UAF1 interac-
tions demonstrated using this assay could be consistently
validated by co-IP in the present study, as well as in our
previous report [18]. Importantly, our data indicate that
USP1S313A forms a functional complex with UAF1 in
transfected cells. This complex is able to reverse mono-
ubiquitination of endogenous PCNA, a well-established
cellular substrate of USP1 [5,15,26,29]. Our results do
not definitely exclude the possibility that S313 phos-
phorylation may modulate the activity of the USP1/UAF1
complex. In fact, minor, but reproducible differences in
the levels of ubPCNA were noted between cells ex-
pressing wild type USP1, USP1S313A or a phosphomi-
metic USP1S313D mutant. In line with previous in vitro
results using an artificial fluorogenic substrate [17], PCNA
deubiquitination appeared to be more efficient in cellsexpressing the S313D phosphomimetic USP1. Never-
theless, S313 phosphorylation does not seem to be an
essential requisite for USP1 activity or UAF1 binding in
a cellular environment.
Our finding that phosphorylation of USP1 at S313 is
dispensable for UAF1 binding in cells, led us to use the
relocation assay to directly compare the relative contri-
bution of two proposed UAF1-binding sites in USP1: the
235–408 fragment containing the S313 residue [17], and
the 420–520 fragment [18]. In marked contrast to the
420–520 fragment, the 235–408 fragment (in either the
S313 wild type or phosphomimetic forms) was unable to
promote the nuclear relocation of UAF1-mRFP. Further-
more, deletion of the 420–520 fragment abrogated UAF1
relocation, regardless of the presence of the S313D phos-
phomimetic mutation. Thus, USP1 420–520 amino acid
motif is both necessary and sufficient for UAF1 binding in
cells. It is important to note that this motif was not tested
in the previous in vitro UAF1-binding assays [17].
The present findings seem to contradict previous in vitro
results showing an interaction of the USP1(235–408)S313D
motif with UAF1. It must be taken into account, however,
that many interacting partners of both USP1 and UAF1
may be present within the crowded environment of intact
cells [30]. If USP1(235–408)S313D interacts weakly with
UAF1, a negative result in the nuclear relocation assay may
be due to competition by endogenous partner(s). In this re-
gard, nuclear import receptors (importins) were obvious
candidates to compete with UAF1 for binding to USP1
(235–408), because USP1 NLSs lie within this motif, and
the importin KPNA1 has been identified as a potential
USP1 interactor [30]. Although USP1 also bears a potential
nuclear export sequence (NES) that could mediate inter-
action with the export receptor CRM1, the physiological
relevance of this sequence remains to be established
[13], and it lies outside the 235–408 segment. Import-
antly, NLS mutations do not increase nuclear relocation
of UAF1-mRFP by USP1(235–408)S313D, suggesting that
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lack of interaction between USP1(235–408)S313D and
UAF1 in a cellular setting.
Altogether, our findings indicate that the USP1 420–
520 fragment is the critical site for robust UAF1-binding
in a cellular environment. In line with this view, the
UAF1-binding site of USP46, another UAF1-interacting
DUB [10], was mapped to amino acids 165–259, which
is a motif homologous to USP1(420–520). The three-
dimensional structure of USP1 and USP46 have not yet
been solved, but in silico modeling using the structure of
USP7 catalytic domain [2] as a template indicates that
USP1(420–520) and USP46(165–259) UAF1-binding mo-
tifs lie within their Fingers sub-domain. Structural analyses
have shown that the Fingers sub-domain contributes to
ubiquitin binding by other members of the USP family
[2,31,32]. Since UAF1 stimulates the deubiquitinating
activity of USP1 and USP46 [7,10], we speculate that
UAF1 and ubiquitin can simultaneously bind to oppos-
ite surfaces of the Fingers sub-domain in these DUBs.
Besides S313 phosphorylation, a well-established mech-
anism regulating USP1 is autocleavage at the G670/G671
diglycine motif [5]. Although originally reported to be
induced by UV light [5], we could readily detect this
cleavage event in 293T cells co-expressing GFP-USP1
and Xpress-UAF1. This observation provided a convenient
experimental system to evaluate two aspects of USP1
autocleavage that have not been tested. On one hand,
we have used co-expression of catalytically inactive
(USP1C90S) and non-cleavable (USP1GG/AA) mutants to
provide some experimental evidence suggesting that USP1
may undergo autocleavage in cis. Due to the technical lim-
itations of our assay, this evidence is not conclusive. A
conceptually similar in vitro test, co-incubating purified
recombinant forms of USP1C90S and USP1GG/AA, could
provide further evidence. On the other hand, we have
evaluated how USP1 autocleavage could be altered by mu-
tations identified in human tumors.
To the best of our knowledge, no functional test on
naturally-occurring USP1 mutations has yet been reported
and thus, the effect that cancer-associated mutations may
have on the function or regulation of USP1 remains unex-
plored. Around forty cancer-associated USP1 mutations
were included in the COSMIC database by September
2013 [13]. Some of these changes were non-sense or
frameshift mutations that would most likely result in a
non-functional allele, but most USP1 mutations lead to
single amino acid substitutions whose effect is still un-
known. Four of these missense mutations, G667A,
L669P, K673T and A676T, are located adjacent or in
close proximity to USP1 autocleavage site, and our data
indicate that one of these changes, the L669P mutation,
decreases USP1 cleavage efficiency. This region of USP1
corresponds to a non-conserved inserted domain betweenboxes 5 and 6, and therefore, no structural information
can be obtained by in silico modeling using other USPs as
template. We hypothesize that this mutation might intro-
duce a conformational change that hampers access of the
cleavage site to the catalytic site. The USP1L669P mutant
clearly retains its ability to deubiquitinate PCNA in
HU-treated cells. It is tempting to speculate that, by
disrupting the normal balance of USP1 cleavage, this
L699P mutation may contribute to tumorigenesis, and
further experiments should address this possibility.
Conclusions
In contrast to previous in vitro findings, or results indi-
cate that USP1 phosphorylation at S313 is not critical
for PCNA deubiquitination, neither for binding to UAF1
in a cellular environment. In this environment, USP1
amino acid motif 420–520 is necessary and sufficient for
UAF1 binding, and thus represents a critical UAF1-binding
site in USP1. This motif, and a homologous amino acid
segment that mediates USP46 binding to UAF1, map to
the Fingers sub-domain of these DUBs. Finally, our results
support the view that USP1 autocleavage may occur in cis,
and show that the balance of USP1 autocleavage can be
disrupted by a cancer-associated mutation.
Methods
Plasmids, cloning procedures and site-directed
mutagenesis
Plasmids encoding GFP-USP1 and Xpress-UAF1 were
generously provided by Dr. Rene Bernards (Netherlands
Cancer Institute, Amsterdam, The Netherlands) and Dr.
Jae U. Jung (University of Southern California, Los Angeles,
USA), respectively. Flag-HA-USP46 was obtained from the
laboratory of Dr. John W. Harper (Harvard Medical School,
Boston, USA) through Addgene (Plasmid #22584). YFP-
USP1 (del420–520) and NLS-USP1(420–520)-GFP plas-
mids have been described previously [18].
To generate the plasmid encoding UAF1-mRFP, UAF1
cDNA was amplified by PCR and cloned in frame to
mRFP using XhoI/AgeI restriction sites. On the other hand,
a DNA sequence encoding USP1 amino acid segment
235–408 was amplified by PCR using GFP-USP1 as a
template, and cloned as either a KpnI/BamHI fragment
into pEYFP-C1 (Clontech), or as a BamHI/AgeI fragment
into a vector termed pNLS(SV40)-GFP. The vector pNLS
(SV40)-GFP derives from a NES-GFP plasmid previously
used in a nuclear import assay [18]. Finally, DNA se-
quences encoding full length USP46 and the three dele-
tion mutants (1–164, 165–259 and 243–366) were amplified
by PCR using Flag-HA-USP46 as a template, and cloned as
BamHI/AgeI fragments into pNLS(SV40)-GFP. Full-length
USP46 was also cloned as a BamHI/AgeI fragment into a
mutant version of pNLS(SV40)-GFP vector carrying a
non-functional NLS sequence to generate the USP46-
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using high fidelity Pfu UltraII fusion HS DNA polymer-
ase (Stratagene).
USP1 point mutations were created using the Quick-
Change Lightning Site-Directed Mutagenesis Kit (Strata-
gene), according to manufacturer’s directions.
All the new constructs generated were subjected to
DNA sequencing (STABVIDA), and the absence of any
unwanted mutation was confirmed. The sequences of
the oligonucleotides used in cloning and site-directed
mutagenesis are available upon request.
Cell culture, transfection and drug treatment
Human embryonic kidney 293T (HEK293T) cells were
grown in Dulbecco’s modified Eagle’s medium (Invitrogen),
supplemented with 10% fetal bovine serum (Invitrogen),
100 U/ml penicillin and 100 μg/ml streptomycin (Invitro-
gen). Twenty four hours before transfection cells were
seeded in 12-well or 6-well tissue culture plates or
10 cm petri dishes. Transfections were carried out with
X-tremeGENE 9 transfection reagent (Roche Diagnostics)
following manufacturer’s protocol.
Hydroxyurea (Sigma-Aldrich) was added to the culture
medium 48 hours after transfection to a final concentra-
tion of 4 mM for 24 hours.
Microscopy analysis of nuclear relocation assay samples
The nuclear relocation assay was carried out in cells seeded
onto sterile glass coverslips. Cells co-expressing UAF1-
mRFP with the different GFP- or YFP-tagged proteins were
fixed with 3.7% formaldehyde in phosphate-buffered saline
(PBS) for 30 min, incubated with Hoechst 33285 (Sigma)
to visualize the nuclei, washed with PBS, and mounted
onto microscope slides using Vectashield (Vector la-
boratories). Single-slice images were acquired using an
Olympus Fluoview FV500 confocal microscope. Sequen-
tial acquisition of each fluorochrome was performed in
order to avoid overlapping of fluorescent emission spectra.
For for live cell imaging, cells were grown in 35 mm
ibiTreat μ-dish slides (Ibidi), transfected with the indi-
cated plasmids and examined using a Zeiss ApoTome.2
microscope. Semiquantitative analysis of nuclear reloca-
tion assay samples was carried out by determining the
nucleocytoplasmic localization of UAF1-mRFP in at least
100 co-transfected cells per slide using a Zeiss Axioskop
fluorescence microscope. Slides were coded to ensure
unbiased scoring, and examined by two independent
observers.
Immunoblot analysis and co-immunoprecipitation
Cells were washed with ice-cold PBS and collected in lysis
buffer containing 10 mM sodium phosphate (pH 7.4),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM β-
glycerophosphate, 0.5% NP40, 10 mM phenylmethylsulfonylfluoride, 10 mM sodium orthovanadate, 10 μg/ml protease
inhibitor cocktail (Roche), and 50 mM N-ethylmaleimide
(Thermo Scientific). Protein concentration was determined
using the DC Protein Assay (Bio-Rad). For immunoblot
analysis, protein samples were resolved in 8%, 10% or
12% SDS-PAGE and transferred onto nitrocellulose mem-
branes (Bio-Rad). Prior to antibody incubation, membranes
were stained with Ponceau to assess protein loading.
Membranes were blocked with 5% non-fat dry milk in
TTBS and incubated with the primary antibodies: anti-
GFP (Chromotek, 1:1000), anti-Xpress (Invitrogen, 1:5000),
anti-PCNA (Santa Cruz, 1:400), anti-β-actin (Sigma-
Aldrich, 1:3000) and anti-α-tubulin (Sigma-Aldrich, 1:3000).
Subsequently, membranes were incubated with the cor-
responding horseradish peroxidase-conjugated second-
ary antibodies (Santa cruz, 1:3000), and developed with
ECL or Femto chemiluminiscence reagents (Thermo
Scientific). Semiquantive analysis of immunoblot bands
was performed by densitometry using Quantity One
software 4.6 (Bio-Rad Laboratories).
Immunoprecipitation of GFP- or YFP-fusion proteins was
carried out using Magnetic GFP-Trap beads (Chromotek),
following manufacturer’s directions. Immunoprecipitated
proteins were analysed by immunoblot as described above.Additional files
Additional file 1: A. Cytoplasmic localization of UAF1-mRFP expressed
alone. Image showing that UAF1-mRFP is cytoplasmic when expressed alone
in 293T cells. This finding suggests that endogenous levels of USP1 are not
sufficient to mediate relocation of ectopically expressed UAF1-mRFP to the
nucleus. B, C. Effect of USP1 siRNA on GFP-USP1-mediated relocation of
UAF1-mRFP. The graph shows the results of a quantitative RT-PCR analysis
to measure endogenous USP1 mRNA level in 293T transfected with control
or USP1-targeted siRNAs. Cells were transfected with scramble siRNA (C(−))
or a pool of three siRNAs targeting USP1 (Ambion, Life Technologies) using
Lipofectamine RNAiMAX transfection reagent (Life Technologies). Total RNA
was isolated using High Pure RNA Isolation Kit (Roche Diagnostics), and
complementary DNA (cDNA) was synthesized using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative real-time
PCR (qRT-PCR) was performed using SYBR Premix Ex Taq (TaKaRa). Gene
expression primers and probes (Integrated DNA Technologies) were used to
specifically amplify USP1 and human GAPDH as an endogenous control. As
shown in the graph, the silencing efficiency was approximately 80% at the
mRNA level. Confocal images show the results of a UAF1-relocation assay in
293T cells first transfected with the corresponding siRNAs (scrambled, left
panels; USP1, right panels), and subsequently with GPF-USP1WT, GFP-
USP1S313A and GFP-USP1S313D. Under these conditions all GFP-USP1
variants were able to efficiently promote relocation of UAF1-mRFP to
the nucleus.
Additional file 2: Whole cell lysate immunoblot allows detection of
PCNA monoubiquitination in response to hydroxyurea treatment.
Image of a complete western blot membrane probed with the anti-PCNA
antibody PC10 (Santa Cruz Biotechnology Ref: sc-56). A clear single band
of the correct size (approximately 30 kDa) is detected in untreated (UT)
293T cells. Following 24 h treatment with 4 mM hydroxyurea (HU), a second
band, with a higher molecular weight (approximately 38 kDa, the expected
size of monoubiquitinated PCNA) is readily detected.
Additional file 3: A. Schematic representation of USP1 protein
illustrating the hypothesis that UAF1 and importins might compete
for binding to USP1(235–408). The UAF1-binding motif reported by
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with USP1 NLSs (red). In order to test this hypothesis, the variant USP1
(235-408NLSm +NLS) (represented below) was generated. In this variant,
USP1 NLSs are inactivated, and its nuclear localization is mediated by
an SV40 NLS fused to its amino terminus. S313 wild type and S313D
phosphomimetic mutants of USP1(235-408NLSm + NLS) were used. B.
Mutation of USP1 NLSs does not result in UAF1 binding to the 235–408
segment. Confocal images showing representative examples of the results
using the in vivo nuclear relocation assay. 293T cells were co-transfected
with UAF1-mRFP and YFP-USP1(235–408), GFP-USP1(235-408NLSm +NLS),
and GFP-USP1(235-408NLSm +NLS)S313D. Cells were counterstained with
Hoechst to show the nuclei (DNA panels).
Additional file 4: Cytoplasmic USP46 can be targeted to the nucleus
by the fusion of a heterologous NLS. Confocal images show that Flag-
HA-tagged and GFP-tagged USP46 (green panels) are localized in the
cytoplasm of transfected 293T cells. However, amino-terminal fusion
of the SV40 NLS sequence (PKKKRKV) leads to nuclear accumulation
of USP46. The nucleocytoplasmic localization of UAF1-mRFP (red panels)
parallels that of the DUB. Cells were counterstained with Hoechst to show
the nuclei (DNA panels).
Additional file 5: (A) The USP1GG/AA autocleavage site mutant
deubiquitinates PCNA. Immunoblot analysis of 293T cells co-transfected
with Xpress-UAF1 and GFP-USP1 wild type (WT), the catalytically inactive
GFP-USPC90S or the autocleavage site mutant GFP-USP1GG/AA. Cells
were treated with 4 mM hydroxyurea (HU) for 24 h. Using an anti-PCNA
antibody, monoubiquitinated PCNA (ubPCNA) is detected as a band
migrating slightly above the non-ubiquitinated form. The image in the
ubPCNA panel was obtained using a longer exposure time. The dotted
line indicates that the panel is a composite of two images from a single
exposure of the same gel. Expression of wild type GFP-USP1 or GFP-
USP1GG/AA decreased PCNA monoubiquitination, whereas expression
of GFP-USP1C90S did not. Expression of β-actin was used as a loading
control. (B) Cancer-associated USP1 mutants relocate UAF1 to the nucleus.
Confocal images showing representative examples of nuclear relocation
assay results with four cancer-associated USP1 mutants. 293T cells were
co-transfected with UAF1-mRFP and YFP vector (negative control), GFP-
USP1G667A, GFP-USP1L669P, GFP-USP1K673T, and GFP-USP1A676T.
Cells were counterstained with Hoechst to show the nuclei (DNA panels).
The four mutants were able to induce the nuclear relocation of UAF1-mRFP,
suggesting that the ability to interact with UAF1 is not disrupted by these
mutations. (C) Mutation of the catalytic C90 residue abrogates autocleavage
of USP1 cancer-related mutants. Immunoblot analysis of 293T cells
co-transfected with different USP1 constructs and Xpress-UAF1. By
introducing a C90S point mutation (S90), the autocleavage of USP1
cancer-related mutants was completely abrogated (note disappearance of
the lower band). Note that the cleavage of L669P is per se very inefficient,
and totally abrogated by the C90S mutation.
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